CrossrefInfokarte
Combined inhibition of PARP and ATR synergistically potentiates the antitumor activity of HER2-targeting antibody-drug conjugate in HER2-positive cancers: Am J Cancer Res. 2023; 13(1): 161-175
American Journal of Cancer Research · 2026 · 16 (10) · 4674-4675
DOI: 10.62347/szdy9971 ↗Abstract
Kein Abstract verfügbar.
EUVIMED